<DOC>
	<DOCNO>NCT00052351</DOCNO>
	<brief_summary>RATIONALE : Vaccines make gene-modified virus may make body build immune response kill tumor cell . Colony-stimulating factor sargramostim may increase number immune cell find bone marrow peripheral blood . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining vaccine therapy sargramostim chemotherapy may kill tumor cell . PURPOSE : Randomized clinical trial study effectiveness vaccine therapy plus sargramostim combination chemotherapy treat woman undergone surgery stage II stage III breast cancer spread lymph node .</brief_summary>
	<brief_title>Vaccine Therapy Plus Sargramostim Chemotherapy Treating Women With Stage II Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare immunological effect 2 different schedule vaccinia-CEA-TRICOM vaccine , fowlpox-CEA-TRICOM vaccine , sargramostim ( GM-CSF ) administer standard adjuvant chemotherapy woman high-risk stage II III breast cancer . - Compare safety regimens patient . - Determine feasibility obtain determination CD4 response patient treat regimen . - Compare disease-free survival patient treat regimen . OUTLINE : This randomize study . Patients randomize 1 2 treatment arm . - Vaccinia-CEA-TRICOM : Beginning 2-3 week surgery initiation standard adjuvant chemotherapy , patient receive vaccinia-CEA-TRICOM vaccine subcutaneously ( SC ) day 1 sargramostim ( GM-CSF ) SC day 1-4 week 1 . - Fowlpox-CEA-TRICOM : Patients treat 1 follow schedule : - Arm I : During chemotherapy , patient receive fowlpox-CEA-TRICOM vaccine SC day 1 GM-CSF SC day 1-4 week 2 , 5 , 8 , 11 , 14 , 17 , 20 , 23 . After chemotherapy , patient receive additional vaccination week 26 , 38 , 50 . - Arm II : Prior chemotherapy , patient receive fowlpox-CEA-TRICOM vaccine SC day 1 GM-CSF SC day 1-4 week 2 . After chemotherapy , patient receive additional vaccination week 26 , 38 , 50 . - Chemotherapy : Patients receive doxorubicin IV 5-7 minute cyclophosphamide IV 30 minute day 1 week 3 , 6 , 9 , 12 . Patients receive paclitaxel IV 3 hour day 1 week 15 , 18 , 21 , 24 . Treatment continue absence disease progression ( least 1 course chemotherapy ) unacceptable toxicity . - Radiotherapy : Patients undergo radiotherapy week 26-32 absence disease progression . Patients hormone-receptor positive tumor receive oral tamoxifen 5 year begin approximately week 32 . Patients follow every 6 month 5 year . PROJECTED ACCRUAL : A total 28 ( 14 per treatment arm ) patient accrue study within 18 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Stage II III At least 4 positive lymph nod No inflammatory ductal carcinoma No positive lymph node immunohistochemistry Carcinoembryonic antigen ( CEA ) expression , indicate 1 following : At least 30 % tumor stain CEA immunohistochemistry Elevated serum CEA ( great 5 ng/mL ) anytime disease course Must HLAA2 positive Must receive prior vaccinia smallpox immunization 1 follow evidence : If age 25 , physician certification prior vaccination If age 25 , patient recollection vaccinationsite scar Any age , detectable antivaccinia antibodies No metastasis CT scan chest , abdomen , pelvis bone scan Hormone receptor status : Estrogen receptor status progesterone receptor status know PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status : Not specify Performance status ECOG 01 Life expectancy Not specify Hematopoietic WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 1.5 time ULN Hepatitis B C negative Renal Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min No proteinuria OR Protein le 1,000 mg per 24hour urine collection No hematuria No abnormal sediment Cardiovascular LVEF least 45 % echocardiogram MUGA either follow true : History cardiac disease Received prior cardiotoxic chemotherapy Immunologic No evidence immunocompromised status No autoimmune disease follow : Autoimmune neutropenia , thrombocytopenia , hemolytic anemia Systemic lupus erythematosus Sjogren 's syndrome Scleroderma Myasthenia gravis Goodpasture syndrome Addison 's disease Hashimoto 's thyroiditis Active Graves ' disease No active prior eczema eczematoid skin disorder No acute , chronic , exfoliative skin condition ( e.g. , atopic dermatitis , burn , impetigo , varicella zoster , severe acne , open rash wound ) HIV negative No active infection within past 3 day No allergy egg No history allergy untoward reaction prior vaccination vaccinia virus Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious illness No malignancy within past 3 year except squamous cell basal cell skin cancer No history seizure , encephalitis , multiple sclerosis No active inflammatory bowel disease Must able avoid close household contact follow 2 week vaccination : Persons active prior eczema eczematoid skin disorder Persons acute , chronic , exfoliative skin condition ( e.g. , atopic dermatitis , burn , impetigo , varicella zoster , severe acne , open rash wound ) Pregnant nurse woman Children 5 year old Immunodeficient immunosuppressed person ( disease therapy ) , include HIV infection PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy No prior doxorubicin , cyclophosphamide , paclitaxel Endocrine therapy No concurrent steroid except follow : Topical steroid Inhaled steroid moderate asthma Dexamethasone prior taxanes Radiotherapy No prior radiotherapy 50 % lymph nod Surgery At least 2 week since prior surgery recover No prior splenectomy Other No concurrent antitumor therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2003</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>